OKYO Pharma Ltd
urcosimod
neuropathic corneal pain (NCP)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on urcosimod for neuropathic corneal pain (NCP) is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“Looking ahead, OKYO Pharma is well-positioned to capitalize on these milestones. With urcosimod’s Fast Track status, promising Phase 2 data, and FDA alignment, we are advancing toward pivotal trials and potential commercialization.”